The skeletal muscle (SKM) injury biomarkers, skeletal troponin I (sTnI), myosin light chain 3 (Myl3), and creatine kinase muscle isoform (Ckm) have been shown recently to be more sensitive and specific for monitoring drug-induced SKM injury than the conventional biomarkers, aspartate transaminase (AST) and creatine kinase (CK) enzymatic assays in rat toxicology studies. To evaluate the utility of these SKM biomarkers across species, they were assessed in 2 dog models: a drug-induced injury study in Beagle dogs and a 160 km endurance exercise run completed by Alaskan sled dogs. In the drug-induced injury model, mean sTnI and Myl3 plasma levels were 6-and 18-fold, respectively, compared with baseline as early as Study Day (SD) 15, while mean plasma AST and CK levels did not increase, and biopsy samples were nonremarkable for histopathology prior to SD 29 when degeneration was first noted. Peak group mean plasma responses over baseline for sTnI, Myl3, and Ckm biomarkers were 96-, 103-, and 11-fold, respectively, compared with 2.5-fold for AST and 3.8-fold for CK-enzymatic (CK-enz) assay. In the sled dog sustained exercise model, the peak response for all biomarkers was observed at the first sampling (2 h) after the completion of the run. The sTnI, Myl3, and Ckm mean fold peak values compared with baseline were 170-, 120-, and 150-fold, respectively, while AST increased 7-fold and CK-enz increased 29-fold. These findings support the conclusion that sTnI, Myl3, and Ckm are sensitive early tissue leakage biomarkers for monitoring SKM injury and effects of exercise in dog, extending their utility across preclinical species beyond the rat, and provide further support to investigate their translational utility to clinical trial settings to monitor for drug-induced SKM injury and ensure patient safety.
Recently, a panel of novel accessible biomarkers of druginduced skeletal muscle (SKM) injury in rat was evaluated through a collaboration of pharmaceutical industry members within The Critical Path Institute's (C-Path) Predictive Safety Testing Consortium Skeletal Muscle Working Group. These novel SKM biomarkers, skeletal troponin I (sTnI), myosin light chain 3 (Myl3), creatine kinase muscle isoform (Ckm), and fatty acid binding protein 3 were shown to outperform the enzymatic assays for aspartate transaminase (AST) and creatine kinase (CK) and/or add value in rat toxicity studies for the diagnosis of drug-induced SKM degeneration and necrosis as well as recovery with greater sensitivity and specificity. SKM biomarkers are high-abundance structural proteins specific to muscles, and upon injury are released into the bloodstream where they can be detected. SKM biomarkers are generally well-conserved between species, and thus are positioned to be used as translational biomarkers in rat, dog, monkey, and human.
Troponin regulates the interaction of myosin with actin necessary for the control of muscle contraction and exists as a complex consisting of 3 subunits: calcium-responsive (C), inhibitory (I), and tropomyosin-binding (T). Troponin I is expressed as 2 V C The Author 2017. Published by Oxford University Press on behalf of the Society of Toxicology. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com isoforms. The cardiac troponin I isoform is specific for heart tissue and has been used clinically as a diagnostic biomarker of various heart conditions for many years (Hoff et al., 2016) . STnI is expressed as slow and fast-twitch forms, and is specific for SKM. STnI is an emerging biomarker of muscle damage in human and rat (Burch et al., 2015 (Burch et al., , 2016 Mullen and Barton, 2000; Simpson et al., 2005; Takahashi et al., 1996) . The cytosolic form of the CK enzyme is responsible for the regeneration of adenosine triphosphate (ATP). It allows cardiac and SKM contraction by transferring the phosphoryl group from phosphocreatine to ADP, resulting in creatine and ATP. Cytosolic CK enzymes consist of 2 subunits, which can be either B (brain type) or M (muscle type). There are, therefore, 3 different isoenzymes CK-MM, CK-BB, and CK-MB. In dog, CK-MM homodimer is the predominant form in both SKM (98%) and heart (90%) (Fredericks et al., 2001) . Myl3 is part of the myosin complex both in cardiac and SKM. Following damage to muscle tissue, the constituent subunits of myosin become dissociated, and Myl3 is released into the bloodstream.
The performance of SKM biomarkers has been demonstrated in rat (Burch et al., 2016) and the potential utility shown in human. However, no data have been published demonstrating their cross-reactivity and use as muscle injury biomarkers in dog. Here we evaluated 2 different models of muscle injury in dog-a drug-induced SKM injury and recovery model and an Alaskan sled dog endurance exercise model. In these models, we demonstrate that sTnI, Myl3, and Ckm are biomarkers suitable for monitoring muscle injury and recovery and effects of exercise in dog with added specificity and sensitivity when compared with AST and CK enzymatic (CK-enz) assay.
MATERIALS AND METHODS
In Vivo Dog Studies Drug-induced muscle injury study. Compound A was administered to male dogs (32-34-weeks old and weighing 8.2-11.7 kg) by oral gavage once daily for approximately 12 weeks followed by a recovery period of 12 weeks. Food was withdrawn overnight prior to scheduled blood sampling for plasma collection, serum biochemical determinations, SKM biopsies, and scheduled necropsies. Water was available ad libitum. The dogs were randomized into 2 groups: treated dogs (8 males) received Compound A as a solution in 0.5% (w/v) methylcellulose in deionized water; the control animals (6 males) received 0.5% (w/v) methylcellulose in deionized water only. In the interim necropsy group, 4 treated dogs and 2 control dogs had biopsies (biceps femoris) performed every 2 weeks beginning on Study Day (SD) 15 until necropsy on SD 84 at which point histopathology on rectus femoris and biceps femoris was performed. In the final necropsy (recovery group), the remaining 4 treated dogs and 4 control dogs had muscle biopsies and histopathology performed on recovery day 1 (SD 85) and at final necropsy on SD 168 (recovery day 84). Blood samples (EDTA plasma) were collected every 2 weeks immediately prior to the biopsies and stored at À70 C until muscle biomarker analyses were performed. This study was reviewed and approved by the Institutional Animal Use and Care Committee.
Exercise Study. The sled dog endurance exercise study and procedures are described in detail in (Brass et al., 2009) . Briefly, dogs were randomly assigned into 2 groups. Ten dogs were run 2 Â 80 km in 24 h with a mid-run 6 h rest period. Four control dogs were kept in their usual housing. All dogs went through conditioning previously; however, were not exercised 72 h prior to the start of this study. Blood samples were collected by jugular venipuncture from all dogs the day before exercise and then at 2, 6, 12, and 24 h after completing the run, processed to plasma, and stored at À70 C until analyses. Histopathological assessment of muscle tissue was not performed.
Biomarker Analyses
Muscle biomarkers were analyzed using rat MSD ELISA kits (Meso Scale Discovery, Gaithersburg, Maryland, USA) according to manufacturer instructions. The Muscle Injury Panel I (sTnI, Myl3, and cardiac troponin I) was analyzed using undiluted plasma or plasma at a 1:2 dilution. Muscle Injury Panel II (Ckm) was analyzed in plasma at 1:5-1:2500 dilutions. Assays were developed for rat and used rat calibrator; however, crossreactivity with dog has been established in our laboratory using muscle tissue homogenates which were prepared by lysing dissected dog tissue in M-PER (Fisher) buffer with a cocktail of proteases inhibitors. Data analysis and comparisons were performed on fold changes to average of study baseline (pretest) and on changes between control and treated groups. Values below the quantifiable levels were replaced by half of the lower limit of quantification (LLOQ).
Statistical Methods
Mixed effects models were fit separately for each biomarker, with fixed effects for treatment, time, and the interaction between treatment and time, and a random effect for individual animals. Hypothesis testing was performed by applying contrasts to estimates obtained from mixed effects models. P-values were corrected for multiplicity using step-up Bonferroni method (Hochberg, 1988) . All response variables were natural log transformed, and calculations were performed using SAS v9.4 (Cary, North Carolina, USA).
Histopathology
The tissues evaluated in the drug-induced study were quadriceps (rectus femoris) and biceps femoris. Tissue sections were fixed in 10% neutral buffered formalin for approximately 24 h, processed and embedded in paraffin. Embedded tissues were cut into 4-6 micron sections and stained with hematoxylin and eosin. Stained tissue sections were examined microscopically and grades were assigned with a severity score scale of 0-5: 0 (no observable pathology), 1 (minimal or very slight), 2 (mild or slight), 3 (moderate), 4 (marked), or 5 (severe).
RESULTS

Animal Studies
Drug-Induced Muscle Injury Study. There were no treatmentrelated physical signs or changes in food consumption. Treatment-related transient body weight loss was observed at Study Weeks 1 through 4 and this loss was maintained over the course of dosing. At study termination, after the treatment-free recovery period, there were no body weight differences between the control and treated animals (see Supplementary Table S1 ) There was a time-dependent increase in the incidence and severity of SKM degeneration (very slight to marked) in treated animals. This was first noted in the muscle biopsies from 2 out of 4 animals on SD 29, and 7 of 8 animals on SD 85 (end of dosing phase). Very slight to slight SKM degeneration was characterized by diffuse, cytoplasmic pallor and rarefaction of the central cytoplasm with loss of myofibril striations. Moderate to marked SKM degeneration was characterized by diffuse and extensive myofiber degeneration, loss of myofibers and regeneration (Figure 1 ). After 12 weeks of recovery (SD 168), the SKM of treated animals were not remarkable for degeneration or necrosis, demonstrating full recovery of SKM histomorphologic changes.
Exercise Study. All dogs completed the run without physical signs suggesting muscle injury (Brass et al., 2009) . Biopsy of the biceps femoris was performed on 2 dogs at 2, 6, and 12 h post exercise and in 3 dogs at 24 h postexercise. Biopsy samples were also collected on control dogs within 2 h of the other dogs starting their run. Each dog was biopsied only once. These muscle samples were used for RNA isolation and histopathological examination was not performed. Results from gene expression changes were published previously (Brass et al., 2009 ).
Biomarker Performance Drug-Induced Muscle Injury Study. Data for individual measurements are shown in Figure 2 and summary data are presented in Table 1 . Cardiac troponin I was measured in all samples and was not increased in any sample (data not shown). STnI values were below the LLOQ in most control animals, so 1/2 the LLOQ was imputed for those samples. STnI and Myl3 differed significantly between control and treated dogs (P < .05) at the first sampling time-point on SD 15 when compared with the average of baseline values (18-and 6-fold change, respectively). At this time-point, no histopathological findings were reported in the biopsy samples-the first SKM degeneration was observed in 2 out of 4 dogs on SD 29. The overall response of all the biomarkers correlated well, with the peak fold increases compared with the average baseline occurring on SD 57 followed by a slight decline in spite of continued daily dosing until SD 85. The peak responses were most prominent in sTnI and Myl3, which were increased 103-and 94-fold, respectively, when compared with baseline, while AST and CK-enz peaked at 2.5-and 3.8-fold increases, respectively. It should be noted that on SD 57 2 out of 4 biopsied dogs still did not have muscle degeneration detected by histopathology but did have increases in the SKM biomarkers, although these increases were considerably lower than the biomarker levels seen in plasma of dogs with positive biopsy findings. This observation suggests enhanced sensitivity of the SKM biomarkers for detecting SKM injury in the biopsy samples. Both dogs with non-remarkable histopathology in the biopsy samples at SD 57 developed SKM degeneration grade 1 at the later time point (SD 85).
The recovery phase started on SD 86 and continued for 12 weeks. During this treatment-free recovery phase all biomarkers trended downward towards the baseline and control levels. At the end of the study, the difference between the treated and the control group was significant only for Ckm. At the final necropsy following the recovery period, no degeneration was observed by histopathology. One dog had findings of very slight (grade 1) focal regeneration in the biceps biopsy. These data demonstrate the ability of the SKM biomarkers to track recovery and regeneration of the SKM.
Exercise Study. Data for individual measurements are shown in Figure 3 and summarized in Table 2 . The peak response for all biomarkers in exercised dogs was observed at the first sampling (2 h) after the 24 h run. STnI had the highest fold change of 170-fold, followed by Ckm (150-fold), Myl3 (120-fold), Ck-enz (29-fold), and AST (7-fold) when compared with baseline. Interestingly, control dogs that did not run also had increases in biomarker levels, although these increases were not as high as those observed in the exercised dogs (Ckm 20-fold, sTnI 18-fold, Myl3 5-fold). Further, the difference between control and exercised dogs was significant (P < .05) at all measured timepoints. All analyzed biomarkers were decreasing towards prerun baseline levels; however, the 24-h period was not long enough to allow for complete recovery of the SKM biomarkers. Myl3 had the slowest decline with 58-fold increase over baseline at the last sampling 24 h after the completion of the run. Even though individual dog biomarker responses varied, the biomarker increases within an individual dog did correlate, with the highest increases in all biomarkers observed in the same dog. Cardiac troponin I was also measured (data not shown) and was elevated (3-fold over the average of baseline) in half of the dogs at 2 h after the exercise. This increase declined over time and there were no cardiac troponin I increases observed at 24 h after the exercise. 
DISCUSSION
There continues to be a need to identify novel accessible biomarkers of end-organ toxicities with improved sensitivity and specificity as tools for assessing tissue injury and as surrogates for histopathological examination. SKM injury biomarkers have been used in humans to study the effect of exercise (Bird et al., 2014; Chapman et al., 2013; King et al., 1976) or various SKM disorders (Burch et al., 2015; Simpson et al., 2005; Takahashi et al., 1996) . SKM toxicity biomarkers have also been evaluated in rat using model muscle toxicants, demonstrating enhanced performance (both superior sensitivity and specificity) relative to the routine use of AST and CK-enz. The ability to monitor for potential myotoxicity in pre-clinical research is important for the determination of the safety of drug candidates. (Burch et al., 2016; Tonomura et al., 2009 Tonomura et al., , 2012 . Dog is a commonly used species in pre-clinical drug-development, and translating novel SKM biomarkers to dog would add value. However, to date, no data have been published regarding the use of SKM injury biomarkers in this species. We evaluated the performance of 3 muscle SKM injury biomarkers (sTnI, Myl3, and Ckm) in a drug-induced injury model and an endurance exercise model. In the drug-induced injury model, all 3 evaluated biomarkers increased with SKM injury and tracked the recovery process with decreasing biomarker plasma levels over time. In the exercise model, peak increases in these biomarkers were observed after the end of exercise and also decreased over time. Even though the levels of the increases varied between individual animals, there was an overall concordance between the biomarkers within an individual animal. In the drug-induced injury model, sTnI, Myl3, and Ckm outperformed AST and CK enzymatic assay in the ability to detect SKM injury earlier, and in both models, with a higher magnitude of change. Although dog sTnI is specific for SKM, both Myl3 and Ckm are present in heart as well (Burch et al., 2016) and therefore injury to cardiac muscle should be considered when increases in these SKM biomarkers are observed. Using cTnI, a biomarker specific for cardiac damage, in conjunction with these SKM biomarkers in a panel approach in such cases is recommended.
The drug-induced SKM injury model evaluated here produced significant SKM injury as determined by histopathology. In several cases, SKM biomarkers were increased in samples where the biopsy sample was non-remarkable for histopathological findings. Given that multiple biomarkers were increased in those samples and the fact that muscle damage was histopathologically observed at a later 
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time-point or within other animals in the treatment group, we hypothesize that SKM biomarker assessment in plasma may be more sensitive than muscle biopsy. To determine if a potential confounding effect of the biopsy procedure may also have impacted the SKM biomarker increases in plasma, 2 control dogs were subjected to the same biopsy schedule and plasma sampling as the treated dogs (plasma samples were always collected immediately prior to the biopsies). SKM biomarkers in the biopsied control dogs did not differ from the control dogs that were not biopsied, demonstrating that the biopsy procedure did not affect measurement of SKM biomarkers and that the 2-week interval between the biopsies is sufficient time to eliminate any SKM biomarkers that may have leaked into the bloodstream due to the procedure.
The exercise study in Alaskan sled dogs provided a good model for studying effects of prolonged endurance exercise on SKM biomarkers. In rare cases of unexpected death during dog races, rhabdomyolysis can be one of the causes and alterations in multiple serum chemistry parameters including cTnI, CKenz, and AST have been reported previously (Dennis et al., 2008; Ermon et al., 2014; McKenzie et al., 2007) . Since histopathological assessment was not performed on SKM in the exercise model, it is difficult to judge the level of possible muscle injury in the running dogs. However, considering the magnitude of biomarker increases that exceeded those observed in the drug-induced injury study, we can hypothesized that SKM injury induced by endurance training was present in these dogs. Interestingly, in our study sTnI, Myl3, and Ckm were also increased in control (not running) dogs when compared with baseline, even though the increases were to a much lesser extent. We hypothesize that one possible cause could be the biopsy procedure that was performed approximately a day before first blood sampling. Another possible contributing factor was that although the control dogs did not exercise with the other dogs, they were moving and running within their kennels extensively in excitement. Both of those activities may have contributed to the increases observed in these sensitive biomarkers. In the dogs that ran, the biopsies were performed only once in each dog at various time points after the completion of the exercise, with 3 dogs biopsied at 24 h postexercise and 1 dog was not biopsied at all. Although the muscle biopsies may have contributed to the overall SKM biomarker increases, this would not be the case in all animals or time points assessed (eg, SKM analyses were performed on samples from exercised dogs prior to the biopsy), supporting that the increases caused by exercise are the major component of overall biomarker response. It should be noted, that the samples were obtained in 2008 and were analyzed at that point with the available MSD assays. Samples were re-analyzed in 2015 with currently available assays and those data are presented here. No decline in concentrations was observed, attesting to the stability of the analytes when properly stored at a À70 for several years.
In conclusion, the data presented here are the first demonstration that sTnI, Myl3, and Ckm are sensitive early SKM injury biomarkers suitable for monitoring SKM injury in dog, extending their utility across preclinical species beyond the rat, and further supporting efforts to qualify their translational utility to clinical settings to monitor SKM injury and ensure patient safety against drug-induced SKM injury in early clinical trials. FIG. 3 . SKM biomarker response in an endurance exercise model of SKM injury in dogs. From a group of 14 dogs, 10 were run for prolonged period of time (see "Materials and Methods" section). Plasma muscle biomarkers levels at baseline and 2, 6, 12, and 24 h after a 160 km run in control (blue circles) and exercised (red squares) dogs. Significant differences (P < .05) between control and treated groups for each biomarker are noted.
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